Home / Stocks / CLOV

Clover Health Investments (CLOV, Managed Health Care) Stock Valuation & Fair Value Trading above fair value

Clover Health Investments (CLOV, Managed Health Care) trades at a blended P/E of 86.8, about 34% above its historical normal valuation, with a forward growth estimate of 59.2% and a PEG of 1.47. Analysts' one-year estimates have been hit 25% of the time. Priced at its historical normal P/E of 65.0 on the same blended earnings, the 2026-09-18 close of $4.46 corresponds to about $3.34 a share. This is a valuation reference, not a price target.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-09-21
Blended P/E
86.8
Normal P/E
65.0
PEG
1.47
Fwd growth
59.2%
Div yield
0.0%
RSI (14)
55.7
Neutral

The Street vs SeerForecast

Wall Street's mean price target for CLOV is $5.38 across 4 analysts, 17.6% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from significantly overvalued (2026-07-31) to trading above fair value (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 164.0 to 86.8 between 2026-07-31 and 2026-09-21, against a normal P/E of 65.0, with 3 rating changes over 18 recorded weeks.2026-07-31: P/E 164.0, Significantly overvalued (recalculated)2026-08-03: P/E 157.8, Significantly overvalued2026-08-07: P/E 157.8, Significantly overvalued (recalculated)2026-08-10: P/E 98.3, Significantly overvalued2026-08-14: P/E 98.3, Significantly overvalued (recalculated)2026-08-17: P/E 94.2, Significantly overvalued2026-08-21: P/E 94.2, Significantly overvalued (recalculated)2026-08-24: P/E 84.3, Trading above fair value2026-08-27: P/E 84.3, Trading above fair value (recalculated)2026-08-28: P/E 84.3, Trading above fair value (recalculated)2026-08-30: P/E 84.3, Trading above fair value (recalculated)2026-08-31: P/E 85.3, Trading above fair value2026-09-05: P/E 85.3, Trading above fair value (recalculated)2026-09-07: P/E 85.1, Trading above fair value2026-09-12: P/E 85.1, Trading above fair value (recalculated)2026-09-14: P/E 94.6, Significantly overvalued2026-09-19: P/E 94.6, Significantly overvalued (recalculated)2026-09-21: P/E 86.8, Trading above fair value75.0100.0125.0150.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 65.0
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 164.0+152%Significantly overvalued
2026-08-24P/E 84.3+30%Trading above fair value
2026-09-14P/E 94.6+45%Significantly overvalued
2026-09-21P/E 86.8+34%Trading above fair value ← now

Frequently asked questions

Is Clover Health Investments stock overvalued?

At a blended P/E of 86.8 versus its historical normal P/E of 65.0, Clover Health Investments trades about 34% above its typical valuation, with a PEG of 1.47 on 59.2% forward growth. tickerseer currently rates it trading above fair value.

What is Clover Health Investments's fair value and PEG?

Clover Health Investments trades at a blended P/E of 86.8 against a historical normal P/E of 65.0, a PEG of 1.47, and a forward growth estimate of 59.2%. Priced at its historical normal P/E of 65.0 on the same blended earnings, the 2026-09-18 close of $4.46 corresponds to about $3.34 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Clover Health Investments changed?

tickerseer's rating moved from significantly overvalued (2026-07-31) to trading above fair value (2026-09-21).

What is the analyst price target for Clover Health Investments?

The mean Wall Street price target for Clover Health Investments is $5.38 across 4 analysts, 17.6% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Managed Health Care. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track CLOV free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.